10. December 2018

Our product highlights, your reliable transglutaminase tools!



Zedira kits


Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | December 2018


Zedi Cup

Get your free Zedi-Coffee-Cup


Use Promo Code Zedi2019
on your next order until January 15th, 2019


An exciting year is almost over. Looking back, it was another inspiring and stimulating year for the transglutaminase

community. All of us will keep the precious moments from the Gordon Research Conference in June in the Swiss Alps in mind.

Drug development programs targeting transglutaminases are moving forward - either via antibodies or small molecules.
Our TG2-blocker ZED1227 entered phase 2a proof-of-concept study in mid 2018.

Zedira is going to continue supporting your R&D efforts, either in academia or in industry with our specialty reagents.


Please find below an extract of our products. You can find more of them and additional information at zedira.com or just contact us (contact@zedira.com).


Sincerely yours,

On behalf of the entire Zedira team
Martin Hils and Ralf Pasternack


Microbial Transglutaminase, MTG

Art. No. Name Unit Price

T001 Microbial (bacterial) transglutaminase
(MTG, recombinantly produced in E. coli,
gene derived from Streptomyces mobaraensis)
25 U
250 U
10x 25 U
500 U
20x 25 U
270 €
2140 €
2140 €
3750 €
3750 €

Z009  
Application:
ZediXclusive Microbial Transglutaminase Assay Kit
Determination of microbial transglutaminase activity

1 Kit 310 €
A145
Immunogen:
Polyclonal antibody to microbial transglutaminase
Microbial transglutaminase (T001), raised in mouse

200 µg 365 €
C102
Application:
MTG-Blocker
Inhibition of microbial transglutaminase, IC50 ~ 125 μM
10 mg
25 mg
210 €
385 €


Tissue Transglutaminase, TG2


Art. No. Name Unit Price

T022 Human tissue transglutaminase
(hTG2, recombinantly produced in insect cells)

250 µg
1 mg
370 €
1100 €
M003
Application:
Tissue Transglutaminase Pico-Assay Kit
Determination of tissue transglutaminase activity

1 Kit 395 €
A028
Format:
FITC-labeled polyclonal antibody to human TG2
A014 purified via affinity chromatography on protein A, followed by FITC-labeling

200 µg 395 €
Z006
Synonym:
Application:
Z-DON-Val-Pro-Leu-OMe, „Z-DON“ 
Z-DON
Irreversible inhibitor of tissue transglutaminase
10 mg 385 €


Coagulation Factor XIII, FXIII

Art. No. Name Unit Price

T027 Human blood coagulation Factor XIII-A2
(hFXIII, A subunit, recombinantly produced in insect cells) 

200 µg 370 €
T070 Human Factor XIIIa, Thrombin activated
(hFXIIIa, recombinantly produced in insect cells)

200 µg 520 €
F001

Application:
FXIII-Assay Kit
Ready to use, contains FXIII-Assay Substance (A101) and thrombin
Fluorescent measurement of transglutaminase activity, optimized for FXIII

1 Kit 575 €
A108
Synonym:
Application:
Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH
ZED1301
Site specific irreversible inhibitor of plasma transglutaminase
5 mg 480 €


Neuronal Transglutaminase, TG6


Art. No. Name Unit Price

T021 Human neuronal transglutaminase
(TG6, recombinantly produced in insect cells)

250 µg 475 €
E103
Antigen:

ZediXclusive TG6-ab ELISA (IgA)
recombinant TG6, insect cells
1 kit/
96 wells 
520 €
E104
Antigen:
ZediXclusive TG6-ab ELISA (IgG)
recombinant TG6, insect cells

1 kit/
96 wells 
520 €
A139
Specificity:
Monoclonal antibody to transglutaminase 6 (Catalytic Domain)
Mouse monoclonal antibody reacts with the Catalytic Domain of human transglutaminase 6

200 µg 365 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • Workshop on Transglutaminase Research

    28.09.2019 - 01.10.2019
    Marrakech, Morocco